The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - AstraZeneca; Celgene; Celltrion; Janssen Oncology; Roche Pharma AG
Speakers' Bureau - Janssen Oncology
Research Funding - Janssen Oncology (Inst); Roche Pharma AG (Inst)
Expert Testimony - AstraZeneca
A phase 1, open-label, multicenter, non-randomized study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of AZD4573, a potent and selective CDK9 inhibitor, in subjects with relapsed or refractory hematological malignancies.
 
Simon Rule
No Relationships to Disclose
 
Arnon P. Kater
Consulting or Advisory Role - Abbvie; Celgene; Janssen Oncology; Sunesis Pharmaceuticals
Research Funding - Celgene (Inst); Gilead Sciences (Inst); Janssen Oncology (Inst); Roche Pharma AG (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Abbvie
 
Tim H. Brümmendorf
No Relationships to Disclose
 
Chris Fegan
No Relationships to Disclose
 
Martin Kaiser
Honoraria - Amgen; Celgene; Takeda
Consulting or Advisory Role - Amgen; Celgene; Janssen Oncology
Research Funding - Celgene (Inst); Janssen Oncology (Inst)
Travel, Accommodations, Expenses - Takeda
 
John A. Radford
No Relationships to Disclose
 
Stephan Stilgenbauer
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Celgene; Gilead Sciences; GlaxoSmithKline; Janssen Oncology; Novartis; Roche Pharma AG
Research Funding - Abbvie (Inst); Amgen (Inst); Celgene (Inst); Gilead Sciences (Inst); Janssen Oncology (Inst); Roche Pharma AG (Inst)
Travel, Accommodations, Expenses - Abbvie; Amgen; AstraZeneca; Celgene; Gilead Sciences; Janssen Oncology; Novartis; Roche Pharma AG
 
Sabine Kayser
No Relationships to Disclose
 
Martin JS Dyer
Honoraria - Abbvie/Genentech; Roche Pharma AG; Sandoz
Speakers' Bureau - Roche Pharma AG
Research Funding - Astex Pharmaceuticals (Inst); Bioinvent (Inst); Gilead Sciences (Inst); Roche Pharma AG (Inst)
Travel, Accommodations, Expenses - Abbvie/Genentech
 
Peter Brossart
No Relationships to Disclose
 
Justin Cidado
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Lisa Drew
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Joe Birkett
No Relationships to Disclose
 
Andrew Davies
Honoraria - Gilead Sciences; Janssen Oncology; Roche Pharma AG
Consulting or Advisory Role - Celgene; Gilead Sciences; Roche/Genentech; Takeda
Research Funding - Acerta Pharma (Inst); Celgene (Inst); Gilead Sciences (Inst); Janssen Oncology (Inst); Roche Pharma AG (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Celgene; Gilead Sciences; Roche Pharma AG; Takeda
 
Wenlin Shao
Employment - AstraZeneca
 
Wolfram Brugger
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
Travel, Accommodations, Expenses - AstraZeneca